Getinge takes a leap forward in cardiovascular surgery with the 510(k) clearance for Vasoview Hemopro 3
Designed with customer centricity top of mind, the newcomer is expected to offer enhanced procedural efficiency in healthcare from the upcoming launch.
- Designed with customer centricity top of mind, the newcomer is expected to offer enhanced procedural efficiency in healthcare from the upcoming launch.
- Receiving the FDA 510(k) clearance for Vasoview Hemopro 3 marks a significant milestone for Getinge and underscores the effort to comply with the highest safety and effectiveness standards, emphasizing the medtech company's commitment to advancing medtech.
- The new generation of Vasoview – Hemopro 3 – symbolizes our dedication to elevating healthcare standards together with our customers," says Elin Frostehav, President Acute Care Therapies at Getinge.
- The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation.